NASH

[Scientific Reports] The authors examined the benefits of serum-free conditioned medium from stem cells derived from human exfoliated deciduous teeth on a murine non-alcoholic steatohepatitis (NASH) model induced by a combination of Western diet and repeated administration of low doses of carbon tetrachloride intraperitoneally, focusing on the gut-liver axis.

[Nature Communications] Researchers developed a simple and robust human liver cell-based system modeling a clinical prognostic liver signature predicting long-term liver disease progression toward hepatocellular carcinoma.

[CohBar, Inc.] CohBar, Inc. announced the United States Patent and Trademark Office has granted a patent, US No. 11,111,271, covering CohBar’s lead candidate CB4211 and related compositions, as well as methods of treatment, including methods of treating NASH.

[Nature Reviews Drug Discovery] The authors intertwine research from biological, clinical and medicinal chemistry disciplines to discuss historical and current RGD-binding integrin drug discovery, with an emphasis on small-molecule inhibitors of the αv integrins.

[Communications Biology] Researchers investigated how liver fibrosis and features of non-alcoholic steatohepatitis (NASH) could be modelled using an in vitro microphysiological system (MPS). The NASH MPS model comprised a co-culture of primary human liver cells, which were cultured in a variety of conditions including +/− excess sugar, fat, exogenous TGFβ or LPS.

[Scientific Reports] Scientists investigated the molecular mechanisms of non-alcoholic fatty liver disease (NAFLD) and fibrosis and identified gene expression clusters that strongly correlated with fibrosis stage including four genes that have been found consistently across previously published transcriptomic studies on non-alcoholic steatohepatitis.